Table 1. Clinical Characteristics
CharacteristicTotal Study PopulationPatients With Non‐CABG‐Related Major Bleeding From Baseline During Follow‐upPatients Without Non‐CABG‐Related Major Bleeding From Baseline During Follow‐up
(n=4049)(n=149)(n=3900)
Age, median (IQR)61(54–70)68(60–74)61(53–70)
Male sex70%(2849)59%(88)71%(2761)
Randomized treatment: Ticagrelor50%(2018)52%(77)50%(1954)
Habitual smoker37%(1509)32%(48)37%(1461)
Hypertension65%(2650)68%(102)65%(2548)
Diabetes mellitus22%(883)26%(39)22%(844)
Previous heart failure5%(219)7%(11)5%(208)
Peripheral arterial disease6%(251)9%(13)6%(238)
Chronic kidney disease8%(312/3908)17%(25)8%(287)
MI before index event20%(794)19%(28)20%(766)
Previous MI/Index event=MI89%(3611)87%(129)89%(3482)
PCI before index event12%(472)14%(21)12%(451)
Previous PCI/in‐hospital PCI74%(2981)83%(124)73%(2857)
Baseline hemoglobin (g/L), median (IQR)142(132–151)136(124–145)142(132–151)
Baseline eGFR (mL/min per 1.73 m2), median (IQR)84(67–101)73.7(55.5–94.3)84.4(67.3–101.4)
  • CABG indicates coronary artery bypass graft surgery; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.